What is Aurealis Pharma?
Aurealis Pharma operates at the intersection of regenerative medicine and oncology, specializing in the development of innovative cell and gene therapies. The company's core platform is engineered to address complex, multi-factorial diseases that have historically proven resistant to conventional treatment modalities. By targeting chronic conditions such as diabetic foot ulcers and various oncological indications, Aurealis Pharma is establishing a unique market position. Their evidence-based approach emphasizes the creation of scalable, cost-effective therapeutic solutions designed to meet significant unmet medical needs, thereby enhancing patient outcomes through precision biotechnology.
How much funding has Aurealis Pharma raised?
Aurealis Pharma has raised a total of $10.8M across 3 funding rounds:
Angel/Seed
$1.8M
Angel/Seed
$3.3M
Series A
$5.8M
Angel/Seed (2014): $1.8M with participation from Tekes
Angel/Seed (2016): $3.3M led by Finnvera plc
Series A (2017): $5.8M supported by Finnvera plc and Tekes
Key Investors in Aurealis Pharma
Tekes
Tekes is a prominent Finnish funding agency that supports researchers in commercializing innovative ideas, providing the necessary resources to transform academic concepts into viable commercial successes.
Finnvera plc
Finnvera is a specialized financing company owned by the State of Finland, acting as the official Export Credit Agency to strengthen the competitiveness and international growth of Finnish enterprises.
What's next for Aurealis Pharma?
With the recent capital injection, Aurealis Pharma is strategically positioned to scale its research and development operations. The company's roadmap involves advancing its lead candidates through critical clinical milestones, ensuring that its multi-target therapeutic platform reaches regulatory maturity. Future growth will likely center on expanding its intellectual property portfolio and strengthening its clinical trial infrastructure. As the firm continues to navigate the complexities of the biotech landscape, this major enterprise-level funding provides the necessary runway to pursue long-term commercialization goals and solidify its role as a leader in the next generation of gene-based medical interventions.
See full Aurealis Pharma company page
